Oct 7
|
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
|
Sep 10
|
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
|
Aug 28
|
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
|
Jun 12
|
Equillium to be included in the Russell Microcap® Index
|
May 29
|
Equillium to Present at the Jefferies Global Healthcare Conference
|
May 14
|
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
|
May 9
|
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
|
May 9
|
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
|
May 7
|
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
|
May 2
|
We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
|
Apr 3
|
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 1
|
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
|
Apr 1
|
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
|
Mar 25
|
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 25
|
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
|
Mar 22
|
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
|
Mar 22
|
Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
|
Mar 4
|
The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
|
Jan 29
|
15 Cash-Rich Penny Stocks Hedge Funds Are Buying
|
Dec 21
|
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
|